2-methyl-7-oxo-4,5,6,7-tetrahydro-benzothiazole-6-carbaldehyde | 51834-72-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-methyl-7-oxo-4,5,6,7-tetrahydro-benzothiazole-6-carbaldehyde
• 英文别名: 6-hydroxymethylene-2-methyl-5,6-dihydro-4H-benzothiazol-7-one；2-Methyl-6-hydroxymethylen-4,5,6,7-tetrahydro-benzothiazol-7-on；2-Methyl-6-hydroxymethylen-4,5,6,7-tetrahydrobenzothiazol；(6Z)-6-(hydroxymethylidene)-2-methyl-4,5-dihydro-1,3-benzothiazol-7-one
• CAS: 51834-72-1
• 化学式: C₉H₉NO₂S
• 分子量: 195.242
• InChiKey: CTFQQNNPLZNBIG-XQRVVYSFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  78.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-methyl-7-oxo-4,5,6,7-tetrahydro-benzothiazole-6-carbaldehyde 在 一水合肼 作用下， 生成 7-methyl-4,5-dihydro-1(2)H-thiazolo[4,5-g]indazole
  参考文献：
  名称：

  Fravolini,A. et al., Gazzetta Chimica Italiana, 1973, vol. 103, p. 755 - 770

  摘要：

  DOI：
• 作为产物：
  描述：

  甲基-2-氧代-7-四氢-4,5,6,7-苯并噻唑 、 甲酸乙酯 在 sodium methylate 作用下， 生成 2-methyl-7-oxo-4,5,6,7-tetrahydro-benzothiazole-6-carbaldehyde
  参考文献：
  名称：

  Fravolini,A. et al., Gazzetta Chimica Italiana, 1973, vol. 103, p. 755 - 770

  摘要：

  DOI：

文献信息

• [EN] 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS<br/>[FR] 2-AMINOPHENYL-4-PHENYLPYRIMIDINES UTILISEES COMME INHIBITEURS DE KINASES
  申请人：CYCLACEL LTD

  公开号：WO2005012262A1

  公开（公告）日：2005-02-10

  The present invention relates to compounds of Formula: (I), or pharmaceutically acceptable salt thereof, wherein the variables are defined in the description. The compounds act as kinase inhibitors.

  本发明涉及式(I)的化合物或其药用可接受的盐，其中变量在描述中有定义。这些化合物作为激酶抑制剂。
• [EN] THIAZOLO-, OXAZALO AND IMIDAZOLO-QUINAZOLINE COMPOUNDS CAPABLE OF INHIBITING PROT EIN KINASES<br/>[FR] COMPOSES A BASE DE THIAZOLO-, OXAZALO ET IMIDAZOLO-QUINAZOLINE CAPABLES D'INHIBITION DE PROTEINE-KINASES
  申请人：CYCLACEL LTD

  公开号：WO2005005438A1

  公开（公告）日：2005-01-20

  compound of formula (1), or a pharmaceutically acceptable salt thereof, wherein: X is S, 0, or NH; 'a' is a single bond; or 'a' is a double bond and one of R3 and R4 and one of R5 and R6 are absent; R1 is H; or is selected from an alkyl group, a cycloalkyl group, a heteroaryl group, an aralkyl group, CO-alkyl, S02-alkyl, C02R13 and an aryl group, each of which optionally contains one or more heteroatoms, and is optionally substituted with one or more groups selected from R8 and R9; R2 is H, R8 , or an alkyl group optionally substituted with one or more R8 groups; R3 , R4, R5, and R6 are each independently selected from H, R8 , an alkyl group and an alkenyl group, wherein said alkyl and alkenyl groups are optionally substituted with one or more R8 groups; or R3 and R4, and/or R5 and R6 together represent =0; R7 is H, R8, NH(CH2)nR9, CO(CH2)nR9, NHCO(CH2)nR9, O(CH2)nR9, or an alkyl or phenyl group, each of which is optionally substituted with one or more groups selected from R8 and R9; R8 is OR10, NR10R11, halogen, CF3, N02, COR10, CN, COOR10, CONR10R11, S02R10 or S02NR10R11; R9 is a saturated or unsaturated 5- or 6-membered cyclic group optionally containing one or more heteroatoms selected from N, 0 and S, and optionally substituted with one or more R8 groups; R10, R11, R12 and R13 are each independently H or a hydrocarbyl group; and n is 0, 1, 2 or 3. Further aspects of the invention relate to pharmaceutical compositions comprising compounds of formula (1), and the therapeutic use thereof in the treatment of proliferative disorders, viral disorders, CNS disorders, diabetes, stroke and cardiovascular disorders.

  化合物的公式（1）或其药学上可接受的盐，其中：X为S、O或NH；'a'为单键；或'a'为双键，且R3和R4中的一个以及R5和R6中的一个不存在；R1为H；或从烷基、环烷基、杂环烷基、芳基、CO-烷基、SO2-烷基、CO2R13和芳基中选择，每种基可选地含有一个或多个杂原子，并可选地用R8和R9中的一个或多个基替代；R2为H、R8或烷基，烷基可选地用一个或多个R8基替代；R3、R4、R5和R6各自独立地选自H、R8、烷基和烯基，其中所述烷基和烯基可选地用一个或多个R8基替代；或R3和R4，和/或R5和R6一起代表=O；R7为H、R8、NH(CH2)nR9、CO(CH2)nR9、NHCO(CH2)nR9、O(CH2)nR9或烷基或苯基，每种基可选地用一个或多个R8和R9中的一个或多个基替代；R8为OR10、NR10R11、卤素、CF3、NO2、COR10、CN、COOR10、CONR10R11、SO2R10或SO2NR10R11；R9为饱和或不饱和的含有一个或多个来自N、O和S的杂原子的5-或6-成员环基，并可选地用一个或多个R8基替代；R10、R11、R12和R13各自独立地为H或烃基；n为0、1、2或3。该发明的进一步方面涉及包含化合物的公式（1）的药物组合物，以及其在治疗增殖性疾病、病毒性疾病、中枢神经系统疾病、糖尿病、中风和心血管疾病中的治疗用途。
• [EN] PYRIMIDIN-4-YL-3, 4-THIONE COMPOUNDS AND THEIR USE IN THERAPY<br/>[FR] COMPOSES DE PYRIMIDIN-4-YL-3, 4-THIONE ET LEUR UTILISATION A DES FINS THERAPEUTIQUES
  申请人：CYCLACEL LTD

  公开号：WO2005042525A1

  公开（公告）日：2005-05-12

  The present invention relates to compounds of formula: (I), or pharmaceutically acceptable salts thereof, wherein R1 and R5 are each independently H, C(ORj’) or a hydrocarbyl group optionally substituted by one or more R6 groups; R2, R3, and R4 are each independently H, alkyl or alkenyl, each of which may be optionally substituted with one or more R7 groups; R6 and R7 are each independently halogen, NO2, CN, (CH2)mORa, O(CH2)nORb, (CH2)pNRcRd, CF3, COORe, CONRfRg, CORh, SO3H, SO2Ri, SO2NRjRk, (CH2)qNRa’CORg’, Rf’, (CH2)rNRb’SO2Rh’, SO2NRd’Ri’, SO2NRe'(CH2)s,ORc', heterocycloalkyl or heteroaryl, wherein said heterocycloalkyl and heteroaryl may be optionally substituted by one or more substituents selected from aralkyl, sulfonyl, Rm and CORn; Rg', Rh', Ri' and Rj' are each independently selected from alkyl, aryl, aralkyl and heteroaryl, each of which may be optionally substituted with one or more substituents selected from halogen, OH, NO2, NH2 CF3 and COOH; m, p, q and r are each independently 0, 1, 2 or 3; n and s are each independently 1, 2, or 3; and Ra-n and Ra'-f' are each independently H or alkyl. Further aspects of the invention relate to pharmaceutical compositions comprising such compounds, and their use in the preparation of a medicament for treating one or more of the following: a proliferative disorder, a viral disorder, a CNS disorder, a stroke, alopecia and diabetes.

  本发明涉及以下结构的化合物：(I)，或其药学上可接受的盐，其中R1和R5分别独立地为H、C(ORj’)或一个或多个R6基团取代的烃基团；R2、R3和R4分别独立地为H、烷基或烯基，每个基团可能选择性地用一个或多个R7基团取代；R6和R7分别独立地为卤素、NO2、CN、(CH2)mORa、O(CH2)nORb、(CH2)pNRcRd、CF3、COORe、CONRfRg、CORh、SO3H、SO2Ri、SO2NRjRk、(CH2)qNRa’CORg’、Rf’、(CH2)rNRb’SO2Rh’、SO2NRd’Ri’、SO2NRe'(CH2)s、ORc'、杂环烷基或杂芳基，其中所述的杂环烷基和杂芳基可以选择性地用一个或多个从芳基烷基、磺酰基、Rm和CORn中选择的取代基团取代；Rg'、Rh'、Ri'和Rj'分别独立地选择自烷基、芳基、芳基烷基和杂芳基，每个基团可能选择性地用一个或多个从卤素、OH、NO2、NH2、CF3和COOH中选择的取代基团取代；m、p、q和r分别独立地为0、1、2或3；n和s分别独立地为1、2或3；以及Ra-n和Ra'-f'分别独立地为H或烷基。本发明的进一步方面涉及包含这种化合物的药物组合物，以及它们在制备治疗以下一种或多种疾病的药物中的用途：增生性疾病、病毒性疾病、中枢神经系统疾病、中风、脱发和糖尿病。
• [EN] PYRIDINYLAMINO-PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS<br/>[FR] DERIVES DE PYRIDINYLAMINO-PYRIMIDINE UTILES COMME INHIBITEURS DE LA PROTEINE KINASE
  申请人：CYCLACEL LTD

  公开号：WO2005012298A1

  公开（公告）日：2005-02-10

  The present invention relates to compounds of formula I, or pharmaceutically acceptable salts thereof, wherein: (A) 'a' is a single bond and 'b' is a double bond; R1 and R2 are each independently as defined below; R10 is absent; or (B) 'a' is a double bond and 'b' is a single bond; R1 is oxygen; R2 is as defined below; and R10 is H or alkyl; X is S, O, NH, or NR 7; Y is N or CR8; one of Z1, Z2, and Z3 is N or N+Ra and the remainder are each independently CR7; R1, R2, R5 and R6 are each independently R7; R3 and R4 are each independently R8; each R7 is independently H, halogen, NRbRC, ORd or a hydrocarbyl group optionally substituted by one or more R9 groups; each R8 is independently H or (CH2)R9, where n is 0 or 1; each R9 is independently selected from H, halogen, NO2, CN, Re, NHCORf, CF3, CORg, NRhRi, CONRJRk, SO2NR1Rm, SO2Rn, ORp, OCH2CH2ORq, morpholine, piperidine and piperazine; and Ra-q are each independently H or alkyl, wherein said alkyl group is optionally substituted by one or more R9 groups; where the compound is other than [4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-yl]-pyridin­2-yl-amine and 4-[4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-N-4­pyridinyl-2-pyrimidinamine. Further aspects of the invention relate to the use of compounds of formula I in the treatment of proliferative disorders, viral disorders, CNS disorders, strokes, alopecia and/or diabetes.

  本发明涉及式I的化合物或其药学上可接受的盐，其中：（A）'a'为单键，'b'为双键；R1和R2各自独立定义如下；R10不存在；或（B）'a'为双键，'b'为单键；R1为氧原子；R2如下定义；R10为H或烷基；X为S、O、NH或NR7；Y为N或CR8；Z1、Z2和Z3中的一个为N或N+Ra，其余各自独立为CR7；R1、R2、R5和R6各自独立为R7；R3和R4各自独立为R8；每个R7各自独立为H、卤素、NRbRC、ORd或一个或多个R9基团可选择地取代的烃基；每个R8各自独立为H或（CH2）R9，其中n为0或1；每个R9各自独立选择自H、卤素、NO2、CN、Re、NHCORf、CF3、CORg、NRhRi、CONRJRk、SO2NR1Rm、SO2Rn、ORp、OCH2CH2ORq、吗啡啉、哌啶和哌嗪；而Ra-q各自独立为H或烷基，其中所述的烷基可以选择地被一个或多个R9基团取代；其中该化合物不是[4-(2,4-二甲基噻唑-5-基)嘧啶-2-基]-吡啶-2-基-胺和4-[4-氟苯基)-1-(1-甲基-4-哌啶基)-1H-咪唑-5-基]-N-4-吡啶基-2-嘧啶胺。本发明的进一步方面涉及使用式I的化合物治疗增殖性疾病、病毒性疾病、中枢神经系统疾病、中风、脱发和/或糖尿病。
• Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases
  申请人：McInnes Campbell

  公开号：US20060264628A1

  公开（公告）日：2006-11-23

  A compound of formula 1, or a pharmaceutically acceptable salt thereof, wherein: X is S, O, or NH; “a” is a single bond; or “a” is a double bond and one of R 3 and R 4 , and one of R 5 and R 6 are absent; R 1 is H; or is selected from an alkyl group, a cycloalkyl group, a heteroaryl group, an aralkyl group, CO-alkyl, SO 2 -alkyl, CO 2 R 13 and an aryl group, each of which optionally contains one or more heteroatoms, and is optionally substituted with one or more groups selected from R 8 and R 9 ; R 2 is H, R 8 , or an alkyl group optionally substituted with one or more R 8 groups; R 3 , R 4 , R 5 , and R 6 are each independently selected from H, R 8 , an alkyl group and an alkenyl group, wherein said alkyl and alkenyl groups are optionally substituted with one or more R 8 groups; or R 3 and R 4 , and/or R 5 and R 6 together represent ═O; R 7 is H, R 8 , NH(CH 2 ) n R 9 , CO(CH 2 ) n R 9 , NHCO(CH 2 ) n R 9 , O(CH 2 ) n R 9 , or an alkyl or phenyl group, each of which is optionally substituted with one or more groups selected from R 8 and R 9 ; R 8 is OR 10 , NR 10 R 11 , halogen, CF 3 , NO 2 , COR 10 , CN, COOR 10 , CONR 10 R 11 , SO 2 R 10 or SO 2 NR 10 R 11 ; R 9 is a saturated or unsaturated 5- or 6-membered cyclic group optionally containing one or more heteroatoms selected from N, O and S, and optionally substituted with one or more R 8 groups; R 10 , R 11 , R 12 and R 13 are each independently H or a hydrocarbyl group; and n is 0, 1, 2 or 3. Further aspects of the invention relate to pharmaceutical compositions comprising compounds of formula 1, and the therapeutic use thereof in the treatment of proliferative disorders, viral disorders, CNS disorders, diabetes, stroke and cardiovascular disorders.

  化合物1的公式，或其药学上可接受的盐，其中：X为S，O或NH；"a"为单键；或"a"为双键，其中R3和R4中的一个，以及R5和R6中的一个缺失；R1为H；或从烷基，环烷基，杂环烷基，芳基烷基，CO-烷基，SO2-烷基，CO2R13和芳基中选择，每个都可以选择性地包含一个或多个杂原子，并且可以选择性地用一个或多个从R8和R9中选择的基团取代；R2为H，R8或烷基，可选择性地用一个或多个R8基团取代；R3、R4、R5和R6各自独立地选择自H、R8、烷基和烯基中的一个，其中所述的烷基和烯基可以选择性地用一个或多个R8基团取代；或者R3和R4，和/或R5和R6一起代表═O；R7为H、R8、NH(CH2)nR9、CO(CH2)nR9、NHCO(CH2)nR9、O(CH2)nR9或烷基或苯基，每个都可以选择性地用一个或多个从R8和R9中选择的基团取代；R8为OR10、NR10R11、卤素、CF3、NO2、COR10、CN、COOR10、CONR10R11、SO2R10或SO2NR10R11；R9为选择性地含有一个或多个R8基团的饱和或不饱和的5或6元环状基团，其中可以选择性地含有一个或多个来自R8的基团；R10、R11、R12和R13各自独立地为H或烃基；n为0、1、2或3。发明的另一方面涉及包括化合物1的制药组合物以及其在治疗增殖性疾病、病毒性疾病、中枢神经系统疾病、糖尿病、中风和心血管疾病中的治疗用途。